Abstract 1638P
Background
Leiomyosarcomas (LMS) are soft tissue sarcomas that derive from smooth muscle and can arise anywhere in the body. The aim of our study was to describe clinical and pathological characteristics and outcomes of patients with LMS diagnosed in our institution from 2001 to 2019.
Methods
A total of 106 patients with LMS were analysed. Clinical and pathological data were collected retrospectively from patients’ electronic board system and statistically analysed. This study was approved by the hospital ethics committee.
Results
The most frequent locations were extremities (29.2%), uterus (22.6%) and retroperitoneum (RP) (19.8%). Most LMS were high grade (6.7% G1, 36% G2, 57.3% G3). Median overall survival (mOS) was 65.4 months (m) for G3 and was not achieved for G2 localized LMS. At diagnoses, most patients had localized disease (68.3%). 43.5% of uterine leiomyosarcomas (uLMS) had metastasis at diagnose compared to 38.8% of LMS located in the extremity, 30% of RP and 27.8% of LMS in other locations (p=0.095). As expected, cutaneous LMS did not develop metastatic disease. Most of localized LMS (82.1%) were > 5cm at diagnosis (median size 9.5cm). For patients with tumours <5cm mOS was 55m compared to 28.4m for >5cm (p=0.03). 80 patients (75%) underwent surgery, including 16.1% of patients with metastatic disease. Perioperative radiotherapy was administered to 42.5% of the patients and 34% received perioperative chemotherapy (CT). A total of 58.8% of patients who underwent radical surgery relapsed. Risk of relapse was higher for uLMS compared to the rest of locations (0% for cutaneous, 50% for extremities, 92.8% for uLMS, 72.2% for RP and 54.5% for other locations LMS) (p=0.007). mOS was 53.6m for uLMS, 90.5m for RP, 53.9m for extremities and 65.4m for other locations (p>0.05). OS for patients with metastatic disease at diagnose was 18.6m for extremities, 13.5m for RP, 10.9m for other locations and 10m for uLMS (p>0.05). The median CT lines was 2 (range 0 – 7). For all locations, the most frequent first line CT was anthracycline-based.
Conclusions
In our series, size and grade are prognostic factors. uLMS had the worse prognosis presenting more frequently with metastatic disease at diagnose and showing a higher risk of relapse after radical surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.